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INTRODUCTION: A.baumannii-calcoaceticus (Abc) complex has surfaced as a major 
nosocomial pathogen causing blood stream infection and ventilators associated 
pneumonia (VAP) and are associated with increased mortality and morbidity. 
Carbapenems are the mainstay of treatment for Abc complex. However, there has been an 
increase incidence of infection with carbapenem resistant strains. Combination antibiotic 
therapy is an approach frequently employed in the treatment of MDR strains, which 
attempts to achieve synergy, particularly against MDR strains. To support this clinical 
practice, in vitro combinations of antibiotics have been examined using checkerboard 
methods, E-tests, and the reference, time-to-kill assay 
 
OBJECTIVES: To determine the minimum inhibitory concentration (MIC) of 
meropenem, sulbactam and colistin by broth micro-dilution technique on the isolates of 
MDR Acinetobacter baumannii-calcoaceticus complex (Abc complex). To determine the 
presence of synergy between sulbactam plus meropenem and sulbactam plus colistin 
combinations by time kill assay at a sub-inhibitory concentration and micro-broth 
checkerboard assay. 
METHODOLOGY: A prospective study was conducted for a duration of one year. 
Twenty five isolates of carbapenem resistant Abc complex cultured from endotracheal 
aspirates of patients admitted in medical and surgical intensive care units diagnosed with 
ventilator associated pneumonia were collected. Isolates were tested for MIC by micro-
broth dilution method for meropenem, sulbactam and colistin. Synergism between 
sulbactam plus meropenem and sulbactam plus colistin was tested by micro-broth 
checkerboard assay and the reference, time kill assay.  
Data was analyzed using SAS software. MIC 50, MIC 90, MIC range and mean MIC were 
estimated for the tested antimicrobial agents. Proportion tests were used to compare the 
outcomes between antibiotics combination. Concordance rate of checker board assay and 
time kill assay were presented.  
 
 
 
RESULTS: MIC ranges (μg/ml) for sulbactam, meropenem, and colistin were 16-512, 
16-256, and 0.5-64 respectively. MIC50 for sulbactam, meropenem, and colistin were 
128, 128 and 1 correspondingly, and MIC90 for sulbactam, meropenem, and colistin were 
256, 256 and 2 respectively. In the checkerboard assay, synergy of 52% and 16% for the 
combination of sulbactam plus meropenem and sulbactam plus colistin, respectively, 
were noted. Time-kill assay showed a synergy of 68% and 32% for the combination of 
sulbactam plus meropenem and sulbactam plus colistin, respectively. Bactericidal activity 
of 80% for sulbactam plus meropenem and 96% for sulbactam plus colistin was 
observed. Antagonism was not detected with any combination or any method.  
 
CONCLUSION: Against MDR isolates of Abc complex commendable synergy was seen 
with time kill assay for sulbactam plus meropenem combination. Significant bactericidal 
activity was observed for both sulbactam plus meropenem/colistin. Therefore, in-vitro 
combinations of antimicrobial agents are most effective than the single agent against 
multidrug resistant organism 
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